Sotatercept Boosts Hemoglobin in MPN-Associated Myelofibrosis

Results from a phase II trial, discussed at the 2017 American Society of Hematology Annual Meeting, show that sotatercept with and without ruxolitinib safely increases hemoglobin levels in patients with MPN-associated myelofibrosis.

 Targeted Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.